Ellen W Kapiteijn

40PUBLICATIONS
151CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsPredictive and prognostic markersRadiation therapyTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Jul 13, 2026
An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

|Jun 24, 2026
Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

|Jan 28, 2026
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Lotte L Hoeijmakers, Petros Dimitriadis, Steven C M A Wijnen

|Dec 15, 2025
No reinduction of clinically relevant radioiodine uptake after lenvatinib treatment in radioidine-refractory differentiated thyroid cancer.

Maaike Dotinga, Lioe-Fee de Geus-Oei, Floris H P van Velden

|Oct 01, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma.

Judith M Versluis, Huma Shehwana, Robert Elens

|May 06, 2025
Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNα.

Els M E Verdegaal, Anique L C Verpoorte, Monique K van der Kooij

Pageof 7

Frequent Collaborators

17 joint publications

Karlijn P M Suijkerbuijk

14 joint publications

Michel W Wouters

9 joint publications

Astrid Van der Veldt

7 joint publications

Monique van der Kooij